High demand for Plasma and Remdesivir
Currently, 55% of global physicians use Hydroxychloroquine, 24% use Tocilizumab, 21% use Remdesivir, 17% use Plasma
High demand for Plasma and Remdesivir
Currently, 55% of global physicians use Hydroxychloroquine, 24% use Tocilizumab, 21% use Remdesivir, 17% use Plasma
Physicians share insights on potential new clinical guidelines, ventilation protocol changes and alternative oxygen therapies
Florida, Texas, Virginia, and Ohio Have Seen Sharpest Increase In Physicians Reporting Infections Among HCP Colleagues; Globally, Russia, Mexico, Brazil & Great Britain Have Seen Sharpest Increase
Majority of Physicians in Many COVID-19 Hotspots Including Korea, Spain, China and Italy Believe Their Countries Have Passed or Reached Outbreak Peak
Kentucky is the Only US State Where More Than 50% of Physicians Recommend Lifting Restrictions Within 2 Weeks
Plasma rated as most safe and effective treatment; 57% of physicians who have used Plasma rate it as highly effective; 60% rate it as safe
Efficacy of treatments as seen by 430 COVID Supertreaters (physicians who’ve treated 20+ COVID patients)
As of April 15, 30% of U.S. physicians vs. 60% in Europe reported getting test results back within a day
Sermo’s Barometer studies have polled over 20,000 physicians globally regarding COVID-19
Percentage of New York Physicians Who Have Used Hydroxychloroquine Nearly Doubled, Italian and French Physicians Jumped 30% Points + Over 2 Weeks
Plasma Still Perceived as Most Effective but Not Widely Used
Perception of Hydroxychloroquine’s Efficacy is Significantly Higher Among Physicians in Europe and China vs US Physicians (50% vs 29%)
69% of hospital physicians globally say their hospitals have already adjusted ventilator prioritization policy in case of shortages; US behind other countries
28% advise daily Vitamin C for protection; traditional Chinese medicine used and found effective among nearly half of Chinese physicians
Data from week two of largest ongoing international market research study on COVID-19
Sermo Reports on Hydroxychloroquine Efficacy, Rise in Prophylaxis Use; Over 80% Expect 2nd Outbreak